Baird Medical Showcases Advanced MWA Technology with UCSF Expert in Guangzhou and Shenzhen
NEW YORK, April 2, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ('Baird Medical' or the 'Company') proudly hosted Dr. Quan-Yang Duh, a world-renowned endocrine surgeon and Chief of Endocrine Surgery at the University of California, San Francisco (UCSF), for an in-depth clinical observation visit in Guangzhou and Shenzhen, China. During his visit, Dr. Duh closely examined the real-world application of Baird Medical's advanced microwave ablation (MWA) technology.
In Guangzhou, Dr. Duh visited several prestigious hospitals, where he observed a range of thyroid ablation cases. One particularly notable case involved a patient with bilateral thyroid nodules, including a 4 cm lesion, successfully treated using Baird Medical's MWA system. The procedure, performed by Dr. Feng Han, a leading MWA specialist at Sun Yat-sen University Cancer Center, was executed with remarkable precision and efficiency. The patient remained fully awake and comfortable throughout underscoring the minimally invasive nature of the procedure.
'The case was highly educational,' said Dr. Duh. 'Dr. Han demonstrated exceptional expertise, and the speed and accuracy of the procedure highlight both the skill of the medical team and the medical team and the sophistication of the technology.' Following the procedure, Dr. Duh engaged in in-depth academic discussions with Dr. Feng Han and Dr. Jian Hua Zhou, Chief of Interventional Radiology at Sun Yat-sen University Cancer Center, further fostering international collaboration in thyroid ablation advancements.
Dr. Duh continued his visit in Shenzhen, where he observed additional MWA procedures at one of the city's leading thyroid hospitals. He also participated in academic discussions with top specialists in the field and delivered a presentation titled 'Advances in Surgical Management of Thyroid and Parathyroid Diseases.' His talk provided valuable insights into the latest developments in endocrine surgery and facilitated an in-depth exchange on the growing role of microwave ablation in thyroid treatment, particularly its integration with surgical approaches.
'We are honored to facilitate these global academic exchanges and showcase the clinical impact of our MWA technology,' said Haimei Wu, Chairwoman of Baird Medical. 'As we continue to expand, we remain committed to driving innovation and working alongside top-tier medical professionals to enhance the accessibility and precision of minimally invasive thyroid treatments.'
As Baird Medical continues its global expansion, the Company remains dedicated to pioneering advancements in microwave ablation technology and forging strategic partnerships that redefine the future of thyroid care.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as 'may', 'could', 'should', 'expect', 'intend', 'might', 'will', 'estimate', 'anticipate', 'believe', 'budget', 'forecast', 'intend', 'plan', 'potential', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled 'Risk Factors' therein, and in ExcelFin's other filings with the SEC.
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Baird Medical Investment Holdings Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
2 Growth Stocks to Stash and 1 to Question
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market's punishment can be swift and severe when trajectories fall. Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. On that note, here are two growth stocks expanding their competitive advantages and one climbing an uphill battle. One-Year Revenue Growth: +25.3% Founded in 2009 by enterprise software veteran Tom Seibel, (NYSE:AI) provides software that makes it easy for organizations to add artificial intelligence technology to their applications. Why Does AI Fall Short? 15.5% annual revenue growth over the last three years was slower than its software peers Extended payback periods on sales investments suggest the company's platform isn't resonating enough to drive efficient sales conversions Historical operating margin losses point to an inefficient cost structure stock price of $25.72 implies a valuation ratio of 7.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than AI. One-Year Revenue Growth: +32.3% Founded in 2014 and named after the dreaded first day of the work week, (NASDAQ:MNDY) is a software-as-a-service platform that helps organizations plan and track work efficiently. Why Is MNDY a Good Business? ARR trends over the last year show it's maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability Software is difficult to replicate at scale and results in a best-in-class gross margin of 89.5% Strong free cash flow margin of 30.4% enables it to reinvest or return capital consistently is trading at $305 per share, or 12.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. One-Year Revenue Growth: +20% Founded in 2010 and named for a combination of 'docs' and 'proximity', Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals. Why Should DOCS Be on Your Watchlist? Billings have averaged 23.5% growth over the last year, showing it's securing new contracts that could potentially increase in value over time Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale DOCS is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $58.44 per share, Doximity trades at 19x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
Yahoo
16 minutes ago
- Yahoo
Nvidia Stock Can Vault to $220 or Plunge to $100, Based on Select Wall Street Analysts -- but Both Price Targets Completely Overlook a Key Catalyst
Artificial intelligence (AI) looks to be the most impactful innovation for corporate America since the advent and proliferation of the internet more than 30 years ago. Compelling arguments from select Wall Street analysts point to Nvidia stock climbing by up to 55% or potentially losing almost 30% of its value. All Wall Street price targets for Nvidia fail to account for a historically accurate catalyst. 10 stocks we like better than Nvidia › More than 30 years ago, the advent and proliferation of the internet kicked off the greatest leap forward in technological innovation for businesses in a long time. Though a number of next-big-thing innovations have come along since the internet revolutionized how businesses interact with consumers and sell their products and services, none have come close to matching its long-term addressable potential... until now. The rise of artificial intelligence (AI) represents the next great tech advancement that has the ability to alter the long-term growth trajectory for corporate America. Empowering software and systems with AI solutions to make decisions without human intervention gives this technology a jaw-dropping addressable market, which the analysts at PwC have pegged at $15.7 trillion (globally) by 2030. Although a long list of companies has benefited from Wall Street's hottest trend, it's semiconductor titan Nvidia (NASDAQ: NVDA) that's become the face of the AI revolution. As is often the case with businesses on the leading edge of a game-changing innovation, predictions are all over the map. Whereas one Wall Street analyst foresees the most pivotal of all tech stocks soaring to $220 per share, another believes it'll plummet to just $100 per share. Yet what's most interesting is that Wall Street's high- and low-water price targets both completely overlook what can arguably be described as the biggest catalyst for Nvidia. Make no mistake about it, the overwhelming majority of Wall Street analysts and investors believe Nvidia stock is headed higher. But none of these price projections speaks louder than analyst Ivan Feinseth at Tigress Financial, who foresees Nvidia shares adding 55% and heading to $220. If Feinseth is accurate, Nvidia's market cap would near $5.4 trillion. For context, Nvidia had a market valuation of $360 billion when 2023 began. Feinseth's Street-high price target is predicated on sustained strong demand for Nvidia's graphics processing units (GPUs). The Hopper (H100) and successor Blackwell GPUs account for the lion's share of the GPUs currently deployed in AI-accelerated data centers, and demand for this hardware hasn't shown any signs of slowing. As a general rule, when the demand for a good or service outstrips its supply, the price of said good or service is going to climb until demand tapers off. In Nvidia's case, its GPU orders are backlogged, which has allowed the company to charge a healthy premium for its hardware, relative to its direct external competitors. The end result has been a significant uptick in the company's gross margin, compared to prior to the AI revolution taking shape. Feinseth's $220 price target, which was issued in late January, came after a short-lived plunge in Nvidia stock caused by the debut of China-based DeepSeek's R1 large language model (LLM) chatbot. DeepSeek is alleged to have used slower and less-costly hardware from Nvidia to develop its LLM. Feinseth's lofty price target demonstrates confidence that Nvidia will be able to maintain its superior pricing power. On the other end of the spectrum is Seaport Global Investors analyst Jay Goldberg. In late April, Goldberg became the only analyst covering Nvidia to rate its stock as a "sell," and initiated a $100 price target. Based on where Nvidia shares ended the session on June 6, Goldberg's price target intimates a decline of almost 30%. Goldberg doesn't foresee Wall Street's AI darling losing its leading position as the preferred company powering AI-accelerated data centers. But he does believe that AI optimism is fully priced into Nvidia stock given a few variables. To begin with, Goldberg notes that many of Nvidia's top customers by net sales are internally developing AI-GPUs and solutions of their own. Even though these chips won't represent external competition for Hopper, Blackwell, or any successor GPUs, they're going to be notably cheaper and more readily accessible than Nvidia's premium-priced and backlogged hardware. This is potentially problematic to Nvidia landing new orders from its current top customers. Goldberg also believes that enterprise customers will branch out and purchase from other hardware providers. For instance, Advanced Micro Devices' less-costly Instinct MI300X series GPUs, as well as Broadcom's custom AI-accelerating chips, could siphon away some of Nvidia's monopoly like data center market share over time. With enterprise spending on AI-data center infrastructure expected to slow in 2026, per Goldberg, Nvidia stock is currently pricey. While Feinseth and Goldberg both make compelling cases, their arguments -- along with the dozens of other analysts and institutions that have placed a price target on shares of Nvidia stock -- completely overlook a historical catalyst associated with next-big-thing trends and innovations. Though the internet proved to be a game-changing technology, it wasn't a universal winner from the get-go. It took years for businesses to figure out how to optimize their marketing and sales to consumers and other businesses. In other words, it took time for the internet to mature as a mainstream innovation. Since the advent of the internet, we've witnessed a number of other high-profile trends, technologies, and innovations come along that have also endured an early stage bubble-bursting event. This includes (but isn't limited to) genome decoding, business-to-business commerce, nanotechnology, 3D printing, cannabis, blockchain technology, and the metaverse. For more than 30 years, investors have consistently overestimated the timeline to mainstream adoption and/or utility for game-changing innovations. In short, investors aren't giving these hyped trends the proper time or channels to mature. Although Nvidia's sales have skyrocketed from $27 billion to more than $130 billion between fiscal 2023 and fiscal 2025 (its fiscal year ends in late January), most businesses are nowhere close to optimizing their AI solutions as of yet, or even generating a positive return on their AI infrastructure investments. This points to the growing likelihood of an AI bubble forming and, at some point, bursting. To be objective, this doesn't mean Nvidia won't be a long-term winner. The proliferation of the internet eventually sent the stock market soaring. While Feinseth's price target may not be achievable in the near-term, it's certainly within the realm of possibilities as businesses learn how to properly utilize AI solutions and generate a profit from their aggressive AI investments. But this historical correlation between next-big-thing trends and bubble-bursting events also suggests Goldberg is likelier to be right in the coming quarters -- albeit not for the reasons put forth in his research note in late April. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Sean Williams has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices and Nvidia. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. Nvidia Stock Can Vault to $220 or Plunge to $100, Based on Select Wall Street Analysts -- but Both Price Targets Completely Overlook a Key Catalyst was originally published by The Motley Fool
Hamilton Spectator
2 hours ago
- Hamilton Spectator
Colliers publishes 2024 Global Sustainability Report
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Colliers (NASDAQ and TSX: CIGI) released its 2024 Global Sustainability Report , highlighting the firm's achievements and progress against targets established in 2021. The report also offers a first look at Colliers' refreshed sustainability strategy, Built to Last , which is based on an updated materiality assessment conducted in the first quarter of 2025. The strategy is designed to align Colliers' priorities with today's most pressing environmental, social, and governance challenges and opportunities, anchored around three core pillars: 'As a global provider of real estate, engineering and investment management services, we are in a unique position to help owner, investor and occupier clients realize their sustainability aspirations while driving the same positive impact for our own operations,' said Jay Hennick, Global Chairman & CEO of Colliers. 'I'm proud of our 2024 performance and remaining agile in our approach to what's next. I look forward to continuing our journey toward a more sustainable future though Built to Last.' Highlights from the 2024 report include: To support the next phase of our sustainability leadership, Tonya Lagrasta has been appointed Global Head of Sustainability at Colliers. A long-time sustainability leader and trusted advisor within our business, Tonya brings more than 20 years of experience across sectors including commercial real estate, retail, consumer goods, financial services, pharmaceuticals, and the public sector. In this role she will spearhead the implementation of Built to Last and drive integration of sustainability across Colliers. 'Sustainability is a reflection of our values in action, and a pathway to long-term resilience,' said Lagrasta. 'Built to Last reflects where we are today – and more importantly, where we're going. I'm energized by our people's passion and proud to help lead this next chapter of impact.' The full 2024 Global Sustainability Report is available at . About Colliers Colliers (NASDAQ, TSX: CIGI) is a global diversified professional services and investment management company. Operating through three industry-leading platforms – Real Estate Services, Engineering, and Investment Management – we have a proven business model, an enterprising culture, and a unique partnership philosophy that drives growth and value creation. For 30 years, Colliers has consistently delivered approximately 20% compound annual returns for shareholders, fueled by visionary leadership, significant inside ownership and substantial recurring earnings. With nearly $5.0 billion in annual revenues, a team of 23,000 professionals, and more than $100 billion in assets under management, Colliers remains committed to accelerating the success of our clients, investors, and people worldwide. Learn more at , X @Colliers or LinkedIn . Media Contact Andrea Cheung Senior Manager, Global Integrated Communications +1 416 324 6402
